POLE encodes a protein for DNA replication. This retrospective study revealed that pathogenic POLE mutations are correlated with TMB-H and associated with a better outcome of immunotherapy.
Garmezy B. et al. 2020 ASCO
In two phase II studies published at the 2020 ASCO Virtual Scientific Program, tipifarnib demonstrated potential anti-tumor effect in head and neck cancer or urothelial cancer patients. All the recruited patients had an HRAS mutation.
J Clin Oncol 38: 2020
According to data reported during the 2020 ASCO Virtual Scientific Meeting, trastuzumab deruxtecan showed promising activity with a high response rate and durable responses among NSCLC patients with HER2 mutation.
J Clin Oncol. 2020
Molecular biomarkers play an important role in NSCLC disease management. There are 11 biomarkers listed in version 4.2020 of the NCCN guideline for NSCLC, including 8 FDA-approved biomarkers and 3 emerging biomarkers for novel therapies. These biomarkers
There is an unmet need for treating the CRC patient who has a KRAS mutation. In a phase 1b/2 study, the combination of onvansertib, FOLFIRI, and bevacizumab as second-line treatment demonstrated significant clinical benefit in KRAS-mutant CRC.
Journal of Clinical Oncology 2020
Currently, there is no approved KRAS targeted therapy, and it remains challenging to treat patients who harbor KRAS mutations. According to preliminary results form an ongoing phase 1 trial, defactinib plus RAF/MEK inhibitor is active in KRAS-mutant cance
For the patients with EGFR T790M, who acquired resistance to first- and second-generation EGFR tyrosine inhibitors, osimertinib demonstrated promising efficacy.
Br J Cancer
A study used ctDNA for evaluation of the resistance mechanisms in HR+/Her2- metastatic breast cancer who were treated with alpelisib plus aromatase inhibitors. The results showed PTEN and ESR1 genetic alterations were associated with resistance.
In addition to breast cancer and gastric cancer, trastuzumab deruxtecan demonstrated promising activity in patients with HER2-expressing and/or HER2-mutant solid tumors in a phase I study.
In a phase 2 clinical trial, addition of trastuzumab to platinum-based chemotherapy showed an overall survival benefit in HER2-positive uterine serous carcinoma patients.
SGO 2020 Annual Meeting